Compared side by side

BPC-157 vs ARA-290: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

BPC-157 is a peptide derived from a protective protein in human gastric juice that, in animal studies, speeds the repair of tendons, ligaments, muscle and gut lining. ARA-290 is 11 amino acids copied from erythropoietin (EPO) that reach its tissue-repair receptor without raising red cells, and its four small randomized phase 2 trials measured nerve symptoms. BPC-157 is taken once or twice daily, commonly for 4–12 weeks; ARA-290’s trials gave it daily for 28 days or 12 weeks.

Side by side

ComparedBPC-157ARA-290
CategoryHealing & recoveryHealing & recovery
Also known asBody Protection Compound 157, BPC157Cibinetide, ARA290, pHBSP, Helix B surface peptide, HBSP
What it isA peptide derived from a protective protein in your stomach.Eleven amino acids copied from the water-facing side of one helix in erythropoietin, the hormone that drives red-cell production — residues that sit side by side on that face, strung into a new chain rather than a stretch cut out of the hormone.
How it worksSynthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining.An 11-amino-acid peptide copied from the water-facing side of helix B in erythropoietin (EPO). It binds the innate repair receptor — the EPO receptor paired with CD131, the beta common receptor — rather than the EPO receptor pair that drives red-cell production, so in lab and animal work it carries EPO's tissue-protective, anti-inflammatory signal without raising red cells. In rats with an injured nerve it reduced allodynia for weeks and damped the spinal microglia response. In people, four small randomized phase 2 trials measured nerve-symptom scores and corneal nerve-fiber density.
Commonly reportedFaster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots.Burning and tingling settling over the first one to two weeks, often with nothing to feel for a while first; one user who ran it for a pinched nerve noticed no change. Four small randomized trials exist and no approval.
Studied rangeResearch range: 200–500 mcg. Studied in research — not a recommendation.Research range: 1–4 mg, starting dose 1 mg. Studied in research — not a recommendation.
How oftenOnce or twice dailyDaily
Half-life~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes)~20 minutes (measured in healthy volunteers after a SubQ dose; about 2 minutes after IV, and its developers argue a brief exposure is enough because the receptor acts as a switch)
RouteSubQ injection, IM injection, Oral (less studied)SubQ injection
Typical runTypically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely.The published daily courses ran 28 days (three trials) and 12 weeks (the eye study). Community runs commonly last about four weeks and are repeated later. In the trial that followed people longest, the symptom improvement was still measurable 12 weeks after the last dose, and nine months after; nothing beyond 12 weeks of daily dosing has been studied.
EvidenceEmerging: primarily preclinical / limited human dataModerate: animal studies + some human data
Common side effectsNausea (rare), injection site irritation, vivid dreams, dizzinessInjection site reaction, headache, light-headedness, fatigue, nausea

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Taking BPC-157 or ARA-290? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

BPC-157

  • Day 1–7 Week one: early hints, for some
  • Day 7–14 Pain often starts to ease
  • Day 14–21 Pain often eases by week three
  • Day 21–28 Many report a calmer gut
  • Day 28–42 The slower part of repair
  • Day 42–56 Six weeks in: taking stock
  • Day 84+ Past week 12, the data runs thin

Every card for BPC-157, with its sources

ARA-290

  • Day 1–14 The first two weeks: for some, the burning eases
  • Day 14–28 Four weeks is where the trials looked
  • Day 28–56 What happened after the dosing stopped
  • Day 56–120 Past the trials' window

Every card for ARA-290, with its sources

Together or one or the other

BPC-157 and ARA-290 are a common stack: ARA-290 lists BPC-157 among its common stacks.

Community · ARA-290

Different jobs: the nerve and the tissue

A pairing the community reaches for when an injury hurts in a nerve way as well as a structural way. The split is honest: ARA-290's human data is about nerve symptoms and nerve-fiber counts, while BPC-157 and TB-500 rest on animal work about blood supply and repair cells moving in. Nothing has tested them together.

Questions people ask

How long do BPC-157 and ARA-290 last?

The half-life of BPC-157 is ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes). The half-life of ARA-290 is ~20 minutes (measured in healthy volunteers after a SubQ dose; about 2 minutes after IV, and its developers argue a brief exposure is enough because the receptor acts as a switch).

How often are BPC-157 and ARA-290 taken?

BPC-157: once or twice daily. Routes: SubQ injection, IM injection, oral (less studied). ARA-290: daily. Route: SubQ injection.

How are BPC-157 and ARA-290 dosed in research?

The research range for BPC-157 is 200–500 mcg. The research range for ARA-290 is 1–4 mg, with a 1 mg starting dose. Studied in research — not a recommendation.

What are the common side effects of BPC-157 and ARA-290?

For BPC-157, the library lists: nausea (rare), injection site irritation, vivid dreams, dizziness. For ARA-290: injection site reaction, headache, light-headedness, fatigue, nausea.

Are BPC-157 and ARA-290 taken together?

BPC-157 and ARA-290 are a common stack: ARA-290 lists BPC-157 among its common stacks. A pairing the community reaches for when an injury hurts in a nerve way as well as a structural way. The split is honest: ARA-290's human data is about nerve symptoms and nerve-fiber counts, while BPC-157 and TB-500 rest on animal work about blood supply and repair cells moving in. Nothing has tested them together.

Each one in full

Track it in the app

PepVault for iPhone

Taking BPC-157 or ARA-290? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo